Shares of Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) have earned an average rating of “Buy” from the twenty brokerages that are presently covering the company, MarketBeat.com reports. Two analysts have rated the stock with a sell rating, five have issued a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the company. The average 12-month price objective among brokers that have issued a report on the stock in the last year is $188.67.

Several brokerages recently issued reports on ICPT. Cantor Fitzgerald reaffirmed an “underweight” rating and set a $69.00 price objective (up from $60.00) on shares of Intercept Pharmaceuticals in a report on Tuesday, August 8th. BidaskClub cut Intercept Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday, August 4th. Laidlaw reaffirmed a “hold” rating and set a $119.00 price objective (up from $115.00) on shares of Intercept Pharmaceuticals in a report on Tuesday, August 1st. Oppenheimer Holdings, Inc. reaffirmed an “outperform” rating and set a $200.00 price objective on shares of Intercept Pharmaceuticals in a report on Tuesday, August 1st. Finally, BMO Capital Markets lifted their price objective on Intercept Pharmaceuticals from $218.00 to $221.00 and gave the stock an “outperform” rating in a report on Tuesday, August 1st.

COPYRIGHT VIOLATION WARNING: This story was first reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this story on another website, it was illegally stolen and republished in violation of United States and international copyright & trademark laws. The original version of this story can be viewed at https://www.thecerbatgem.com/2017/08/18/intercept-pharmaceuticals-inc-icpt-receives-average-rating-of-buy-from-brokerages.html.

Intercept Pharmaceuticals (NASDAQ:ICPT) opened at 104.19 on Friday. The firm’s market capitalization is $2.62 billion. The stock’s 50 day moving average price is $118.27 and its 200 day moving average price is $117.70. Intercept Pharmaceuticals has a 52 week low of $96.63 and a 52 week high of $172.95.

Intercept Pharmaceuticals (NASDAQ:ICPT) last issued its quarterly earnings data on Monday, July 31st. The biopharmaceutical company reported ($3.46) earnings per share (EPS) for the quarter, topping the consensus estimate of ($3.62) by $0.16. The firm had revenue of $30.89 million during the quarter, compared to analysts’ expectations of $27.50 million. Intercept Pharmaceuticals had a negative return on equity of 135.24% and a negative net margin of 543.35%. Intercept Pharmaceuticals’s revenue was up 459.6% on a year-over-year basis. During the same period in the previous year, the firm posted ($3.14) earnings per share. On average, equities analysts expect that Intercept Pharmaceuticals will post ($14.05) EPS for the current year.

In related news, insider Lisa Bright sold 698 shares of the company’s stock in a transaction on Thursday, June 1st. The stock was sold at an average price of $110.73, for a total value of $77,289.54. Following the completion of the transaction, the insider now directly owns 24,711 shares in the company, valued at $2,736,249.03. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Mark Pruzanski sold 40,000 shares of the company’s stock in a transaction on Monday, June 26th. The shares were sold at an average price of $130.80, for a total value of $5,232,000.00. Following the completion of the transaction, the chief executive officer now owns 611,718 shares of the company’s stock, valued at $80,012,714.40. The disclosure for this sale can be found here. Insiders sold 47,462 shares of company stock valued at $6,130,938 over the last quarter. Insiders own 9.20% of the company’s stock.

A number of institutional investors have recently added to or reduced their stakes in ICPT. Zurcher Kantonalbank Zurich Cantonalbank raised its position in Intercept Pharmaceuticals by 14.4% in the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,047 shares of the biopharmaceutical company’s stock valued at $118,000 after buying an additional 132 shares during the last quarter. US Bancorp DE acquired a new position in Intercept Pharmaceuticals during the first quarter valued at approximately $130,000. IFP Advisors Inc raised its position in Intercept Pharmaceuticals by 128.1% in the second quarter. IFP Advisors Inc now owns 1,300 shares of the biopharmaceutical company’s stock valued at $157,000 after buying an additional 730 shares during the last quarter. Quantbot Technologies LP acquired a new position in Intercept Pharmaceuticals during the first quarter valued at approximately $170,000. Finally, Pacer Advisors Inc. raised its position in Intercept Pharmaceuticals by 21.6% in the first quarter. Pacer Advisors Inc. now owns 1,861 shares of the biopharmaceutical company’s stock valued at $210,000 after buying an additional 330 shares during the last quarter. Hedge funds and other institutional investors own 83.05% of the company’s stock.

Intercept Pharmaceuticals Company Profile

Intercept Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company’s product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions.

Analyst Recommendations for Intercept Pharmaceuticals (NASDAQ:ICPT)

Receive News & Stock Ratings for Intercept Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.